Log in

Relevant bibliographies by topics / Tyrosinase inhibitors / Books

To see the other types of publications on this topic, follow the link: Tyrosinase inhibitors.

Books on the topic 'Tyrosinase inhibitors'

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 31 books for your research on the topic 'Tyrosinase inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Focosi, Daniele, ed. Resistance to Tyrosine Kinase Inhibitors. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46091-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Cunningham, Bernadette Deirdre Mary. Flavones and related compounds as inhibitors of protein tyrosine kinases. Aston University. Department of Pharmaceutical Sciences, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kotoris, Christopher C. Studies on intramolecular peptide bond cleavage and design and synthesis of protein tyrosine phosphatase inhibitors. National Library of Canada, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tsiani, Evangelia. Regulation of metabolic effects in L6 muscle cells by sulfonylureas and the protein tyrosine phosphatase inhibitors vanadate and pervanadate. National Library of Canada = Bibliothèque nationale du Canada, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Matthews, David J. Targeting protein kinases for cancer therapy. John Wiley & Sons, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

E, Gerritsen Mary, ed. Targeting protein kinases for cancer therapy. John Wiley & Sons, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Rommel, Christian. Phosphoinositide 3-kinase in Health and Disease: Volume 2. Springer-Verlag Berlin Heidelberg, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Phosphoinositide 3-kinase in health and disease. Springer Verlag, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer International Publishing AG, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Full text

Abstract:

Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling

APA, Harvard, Vancouver, ISO, and other styles

13

D, Fabbro, and McCormick Frank 1950-, eds. Protein tyrosine kinases: From inhibitors to useful drugs. Humana Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

McCormick, Frank, and Doriano Fabbro. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

McCormick, Frank. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text

Abstract:

Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor

APA, Harvard, Vancouver, ISO, and other styles

17

(Editor), Doriano Fabbro, and Frank McCormick (Editor), eds. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kotoris, Christopher C. The synthesis of novel organofluorines by electrophilic fluorination and their evaluation as inhibitors of protein tyrosine phosphatase 1B. Dept of Chemistry, U of Toronto, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

(Editor), Marc Daeron, and Eric Vivier (Editor), eds. Immunoreceptor Tyrosine-based Inhibition Motifs (Current Topics in Microbiology and Immunology). Springer, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Grzyb, Justyna. Synthesis of non-peptidyl [alpha],[alpha]-difluoromethylenephosphonic acids on a soluble polymer support and their evaluation as inhibitors of protein tyrosine phosphatase 1B. Dept of Chemistry, U of Toronto, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hum, Gabriel. Novel approaches towards the synthesis of protein tyrosine phosphatase inhibitors and alternative strategies in the design of transition state analogues for phosphatase abzymes. 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Leung, Carmen. Synthesis of [alpha], [alpha]-difluoromethylenesulfonic acids on a soluble polymer support and their evaluation as inhibitors of protein tyrosine phosphatases and aryl sulfatases. 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Harney, Dennis J. A kinetic study of the enzyme systems deaminating phenylalanine and tyrosine using the specific PAL inhibitor 2-aminoindan-2-phosphonic acid (AIP). 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Kuwabara, Satoshi. Neuromuscular junction disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199658602.003.0014.

Full text

Abstract:

Ten seminal papers on disorders of the neuromuscular junction are described, covering historical aspects, recent advances in immunological, biological, and genetic researches, and future perspectives. Early descriptions of myasthenia gravis (MG) date back to the seventeenth century, and MG acquired its name in the nineteenth century. The first symptomatic treatment with cholinesterase inhibitors was reported in 1934, leading to the development of modern immunological therapies. Following the discovery of anti-MuSK (muscle-specific tyrosine kinase) antibody in 2001, MG is currently classified i

APA, Harvard, Vancouver, ISO, and other styles

25

McCann, Shaun R. Leukaemia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0007.

Full text

Abstract:

The word leukaemia still is associated with foreboding and a fear of premature death. Steady advances have been made in the treatment of childhood leukaemia but, with notable exceptions, the same is not true in adults. The so-called genetic/molecular revolution has extended the understanding of the pathogenesis of many forms of leukaemia but, as yet, has rarely facilitated cure. With the introduction of tyrosine kinase inhibitor therapy, chronic myeloid leukaemia is the obvious exception but it still needs to be seen as to whether the cytogenetic/molecular revolution can provide cures for many

APA, Harvard, Vancouver, ISO, and other styles

26

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text

Abstract:

Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen

APA, Harvard, Vancouver, ISO, and other styles

27

Stafstrom, Carl E., and Thomas P. Sutula. 2-Deoxyglucose. Edited by Dominic P. D’Agostino. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.003.0036.

Full text

Abstract:

Metabolic regulation of excitability is increasingly appreciated as a strategy to control seizures and reduce pathogenesis. Inhibiting or bypassing glycolysis may be one way in which the ketogenic diet suppresses seizures. 2-deoxy-D-glucose (2DG) is a glucose analog that partially inhibits glycolysis and has antiseizure effects in several acute and chronic seizure models. The mechanisms underlying the acute and chronic effects of 2DG are being investigated. Preliminary studies provide evidence that the acute anticonvulsant actions of 2DG involve activity-dependent presynaptic suppression of ex

APA, Harvard, Vancouver, ISO, and other styles

28

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-kinase in Health and Disease: Volume 1. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-kinase in Health and Disease: Volume 2. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-Kinase in Health and Disease: Volume 2. Springer Berlin / Heidelberg, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-kinase in Health and Disease: Volume 1. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!